Company: MDCXW
Filing Date: 2025-05-05
Form Type: 424B3
Source: 0001062993-25-008444
Chunk: 53

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-05
Form: 424B3
Chunk 53
---
1, respectively, and are incorporated herein by reference.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information contained in Item 1.01 of this Current Report on Form 8-K is incorporated by reference herein in its entirety.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

| Exhibit 
 No.     
 4.1*    
 10.1*#  
 10.2*   |     | Description                                                                                                                                                                                                                                       
 Form of Debenture.                                                                                                                                                                                                                                
 Securities Purchase Agreement, by and between Medicus Pharma Ltd. and YA II PN, Ltd., dated May 2, 2025.                                                                                                                                          
 Global Guaranty Agreement, by and among the subsidiaries of Medicus Pharma Ltd. set forth in Schedule I thereto, dated May 2, 2025.                                                                                                               |
|:--------|:----|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 104     |     | Cover Page Interactive Data File (formatted as Inline XBRL document).                                                                                                                                                                             |
| *       |     | Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. The Company agrees to furnish supplementally an unredacted copy of the exhibit to the Securities and Exchange Commission upon its request. |
| 

#       |     | Certain schedules and exhibits have been omitted in accordance with Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.                     |
Forward Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements include, but are not limited to, statements concerning the principal aggregate amount of Debentures the Company may issue, the potential early redemption of the amounts outstanding under the Debentures by either the Company or Yorkville, the terms and conditions of the Debentures, including with respect to the Company filing an effective registration statement with the SEC. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. In addition, forward-looking statements are typically identified